Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in japanese patients with type 2 diabetes on insulin therapy

Diabetes Technology and Therapeutics

Volumn 16, Issue 12, 2014, Pages 840-845

  Tanaka, Seiichi ^a   Suzuki, Kunihiro ^a   Aoki, Chie ^a   Niitani, Mai ^a   Kato, Kanako ^a   Tomotsune, Takanori ^a   Aso, Yoshimasa ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; ANTIDIABETIC AGENT; C REACTIVE PROTEIN; GLUCOSE; GLYCOSYLATED ALBUMIN; HIGH SENSITIVITY C REACTIVE PROTEIN; INSULIN; TENELIGLIPTIN; UNCLASSIFIED DRUG; 1,5-ANHYDROGLUCITOL; 3-(4-(4-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)PIPERAZIN-1-YL)PYRROLIDIN-2-YLCARBONYL)THIAZOLIDINE; DEOXYGLUCOSE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED SERUM ALBUMIN; PYRAZOLE DERIVATIVE; SERUM ALBUMIN; THIAZOLIDINE DERIVATIVE;

ADD ON THERAPY; ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; DIABETIC PATIENT; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; JAPANESE (PEOPLE); MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; ADVERSE EFFECTS; AGED; AMBULATORY MONITORING; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIET THERAPY; DRUG COMBINATION; DRUG RESISTANCE; HYPERGLYCEMIA; JAPAN; MIDDLE AGED; MULTIDRUG RESISTANCE; MULTIMODALITY CANCER THERAPY;

AGED; C-REACTIVE PROTEIN; COMBINED MODALITY THERAPY; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DIET, DIABETIC; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; JAPAN; MALE; MIDDLE AGED; MONITORING, AMBULATORY; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRAZOLES; SERUM ALBUMIN; THIAZOLIDINES;

EID: 84914179213     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2014.0095     Document Type: Article

References (27)

1. Drucker DJ: The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
2. Holst JJ: The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439
3. Drucker DJ, Nauck MA: The incretin system: glucagonlike peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705
4. Aso Y, Terasawa T, Kato K, et al.: The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes. Transl Res 2013;162:309-316
5. Xu L, Man CD, Charbonnel B, et al.: Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008;10:1212-1220
6. Deacon CF: Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011;13:7-18
7. Mori Y, Taniguchi Y, Matsuura K, et al.: Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring. Diabetes Technol Ther 2011;13:699-703
8. Kadowaki T, Kondo K: Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:810-818
9. Nabeno M, Akahoshi F, Kishida H, et al.: A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochem Biophys Res Commun 2013;434:191-196
10. Kim D, Wang L, Baconi M, et al.: (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-A]pyrazin-7(8H)-yl]-1-(2,4,5-Trifluorophenyl)butan-2-Amine: a potent, orally activate dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 2005;48:141-151
11. Metzler WJ, Yanchunas J, Weighlt C, et al.: Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci 2008;17:240-250
12. Eckhardt M, Langkopf E, Mark M, et al.: 8-(3-(R)-Aminopiperidin-1-yl)-7-buut-2-ynyl-3-methyl-1-(4-methylquinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-Acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 2007;50:6450-6453
13. Zhang Z, Wallance MB, Feng J, et al.: Design and synthesis of pyrimidinone and pyridinedione inhibitors of dipeptidyl peptidase IV. J Med Chem 2011;54:510-524
14. Villhauer EB, Brinkman JA, Naderi GB, et al.: 1-[[(3-Hydroxy-1-Adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 2003;46:2774-2789
15. Katsuno T, Ikeda H, Ida K, et al.: Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-Treated Japanese patients with type 2 diabetes mellitus. Endocr J 2013;60:733-742
16. Kothny W, Foley J, Kozlovski P, et al.: Improved glycemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:252-257
17. Lukashevich V, Schweizer A, Foley JE, et al.: Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013;9:21-28
18. Mori Y, Taniguchi Y, Miyazaki S, et al.: Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy. Diabetes Technol Ther 2013;15: 237-240
19. Fravel MA, McDanel DL, Ross MB, et al.: Special considerations for treatment of type 2 diabetes mellitus in the elderly. Am J Health Syst Pharm 2011;68:500-509
20. Sakamoto M, Nishimura R, Irako T, et al.: Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study ( J-VICTORIA study). Cardiovasc Diabetol 2012;11:92
21. VilsbØll T, Rosenstock J, Yki-Järvinen H, et al.: Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010;12: 167-177
22. Monnier L, Mas E, Ginet C, et al.: Activation of oxidative stress by acute fluctuations compared with sustained chronic hyperglucemia in patinets with type 2 diabetes. JAMA 2006; 295:1681-1687
23. Suzuki K, Olar G, Modis K, et al.: Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial function. Proc Natl Acad Sci USA 2011;108:13829-13834
24. Moreno G, Mangione CM: Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review. J Am Geriatr Soc 2013;61:2027-2037
25. Satoh-Asahara N, Sasaki Y, Wada H, et al.: A dipeptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. Metabolism 2013;62:347-351
26. Osonoi T, Saito M, Tamasawa A, et al.: Effects of sitagliptin or mitiglinide as an add-on to acarbose on Daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized study. Expert Opin Pharmacother 2014;15:1325-1335
27. Kim HS, Shin JA, Lee SH, et al.: A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther 2013;15:810-816